Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Haematologica. - 105, 5 (2020) , 1183-1188, ISSN: 1592-8721
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2020
- Urheber
- DOI
-
10.3324/haematol.2019.242958
- URN
-
urn:nbn:de:bsz:25-freidok-1657328
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Engelhardt, Monika
- Ihorst, Gabriele
- Duque Afonso, Jesús
- Wedding, Ulrich
- Spät-Schwalbe, Ernst
- Goede, Valentin
- Kolb, Gerald
- Stauder, Reinhard
- Wäsch, Ralph
- Universität
Entstanden
- 2020
Ähnliche Objekte (12)
Response to daratumumab-retreatment in patients with multiple myeloma
Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with long‐term follow‐up of 815 patients
The role of the APC/C and its coactivators Cdh1 and Cdc20 in cancer development and therapy
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Clinical characteristics, cytogenetic risks, and prognoses of young multiple myeloma patients in the era of novel therapies
Geriatric assessments and frailty scores in multiple myeloma patients : : a needed tool for individualized treatment?
Osteoprotective medication in the era of novel agents : : a european perspective on values, risks and future solutions
Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort
Allogeneic stem cell transplantation in multiple myeloma
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
In search of the optimal proteosome inhibitor. How, when and for whom?
Das interdisziplinäre Tumorboard „Multiples Myelom“ des Comprehensive Cancer Center Freiburg: eine Reanalyse
Response to daratumumab-retreatment in patients with multiple myeloma
Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with long‐term follow‐up of 815 patients
The role of the APC/C and its coactivators Cdh1 and Cdc20 in cancer development and therapy
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Clinical characteristics, cytogenetic risks, and prognoses of young multiple myeloma patients in the era of novel therapies
Geriatric assessments and frailty scores in multiple myeloma patients : : a needed tool for individualized treatment?
Osteoprotective medication in the era of novel agents : : a european perspective on values, risks and future solutions
Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort
Allogeneic stem cell transplantation in multiple myeloma
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
In search of the optimal proteosome inhibitor. How, when and for whom?
Das interdisziplinäre Tumorboard „Multiples Myelom“ des Comprehensive Cancer Center Freiburg: eine Reanalyse
Response to daratumumab-retreatment in patients with multiple myeloma
Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with long‐term follow‐up of 815 patients
The role of the APC/C and its coactivators Cdh1 and Cdc20 in cancer development and therapy
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Clinical characteristics, cytogenetic risks, and prognoses of young multiple myeloma patients in the era of novel therapies
Geriatric assessments and frailty scores in multiple myeloma patients : : a needed tool for individualized treatment?
Osteoprotective medication in the era of novel agents : : a european perspective on values, risks and future solutions
Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort
Allogeneic stem cell transplantation in multiple myeloma
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
In search of the optimal proteosome inhibitor. How, when and for whom?